Yahoo · Sep 18, 2026
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $508.34, signifying a -1.55% move from its prior day's close.
NASDAQ · VRTX
Vertex Pharmaceuticals Incorporated
Healthcare · Biotechnology
$508.34
Down-$8.00 (-1.55%)
Updated Sep 20, 2026, 11:40 AM
SID Score
6.2/10
Composite research score
Smart Money
59/100
Neutral
- Market cap
- 114.46B
- P/E ratio
- 31.02
- Dividend yield
- 0.00%
- 52-week range
- $412.27 – $560.25
- Volume
- 2.43M
- Avg. volume
- 1.51M
Price performance
VRTX price history
1M range · 19 trading sessions · Daily adjusted prices
VRTX closed at $508.34 after 19 trading sessions, down 7.17% for the selected period.
- Last close
- $508.34
- Period change
- -7.17%
- Period low
- $508.34
- Period high
- $557.96
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $516.34 | $518.10 | $505.01 | $508.34 | 2.43M |
| Sep 17, 2026 | $518.35 | $519.07 | $510.195 | $516.34 | 900.05K |
| Sep 16, 2026 | $513.80 | $517.95 | $511.35 | $513.26 | 638.51K |
| Sep 15, 2026 | $519.94 | $519.94 | $511.001 | $514.63 | 824.89K |
| Sep 14, 2026 | $522.17 | $525.29 | $514.655 | $519.51 | 837.11K |
| Sep 11, 2026 | $522.10 | $522.10 | $511.81 | $515.44 | 875.64K |
| Sep 10, 2026 | $519.13 | $522.60 | $514.32 | $514.56 | 815.17K |
| Sep 9, 2026 | $524.00 | $528.165 | $520.08 | $521.12 | 958.51K |
| Sep 8, 2026 | $529.64 | $535.00 | $520.20 | $528.90 | 1.12M |
| Sep 4, 2026 | $549.50 | $556.99 | $544.48 | $546.12 | 803.52K |
| Sep 3, 2026 | $559.00 | $560.25 | $551.61 | $557.96 | 800.96K |
| Sep 2, 2026 | $552.42 | $558.36 | $549.07 | $556.75 | 1.73M |
| Sep 1, 2026 | $548.60 | $551.40 | $545.08 | $547.65 | 735.12K |
| Aug 31, 2026 | $535.38 | $546.84 | $532.2281 | $544.52 | 1.2M |
| Aug 28, 2026 | $547.09 | $549.57 | $540.08 | $541.69 | 886.92K |
| Aug 27, 2026 | $540.08 | $550.83 | $540.08 | $547.55 | 844.62K |
| Aug 26, 2026 | $549.84 | $553.47 | $546.235 | $547.29 | 834.38K |
| Aug 25, 2026 | $545.53 | $555.69 | $543.75 | $552.85 | 775.04K |
| Aug 24, 2026 | $548.98 | $550.615 | $542.42 | $547.59 | 767.49K |
Latest VRTX news
The latest Smart Investors Daily articles mentioning VRTX.
Stock researchCompany · Overview
VRTX research
Overview
Company profile and research snapshot.
Company profile
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $483.00
- Implied upside
- —
- Analysts
- 23
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 11, 2026 | JP Morgan | Overweight | — |
| Sep 2, 2026 | Morgan Stanley | Overweight | — |
| Aug 5, 2026 | Truist Securities | Buy | — |
| Aug 5, 2026 | Barclays | Overweight | — |
| Aug 4, 2026 | TD Cowen | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 18, 2026
2 Reasons to Like VRTX (and 1 Not So Much)
Vertex Pharmaceuticals has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13.9% to $514.18 per share while the index has gained 14%.
Yahoo · Sep 18, 2026
Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback?
This company has had plenty of setbacks in recent years, but it generally bounces back.
Yahoo · Sep 18, 2026
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?
With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
